Intracerebral Interleukin 12 Induces Glioma Rejection in the Brain Predominantly by CD8+ T Cells and Independently of Interferon-&ggr;

@article{Vetter2009IntracerebralI1,
  title={Intracerebral Interleukin 12 Induces Glioma Rejection in the Brain Predominantly by CD8+ T Cells and Independently of Interferon-\&ggr;},
  author={M. Vetter and M. Hofer and E. Roth and H. Pircher and A. Pagenstecher},
  journal={Journal of Neuropathology and Experimental Neurology},
  year={2009},
  volume={68},
  pages={525-534}
}
The prognosis of gliomas is generally poor since these tumors elude established therapeutic approaches. Immunotherapy might present an effective therapy in particular because the glioma cells are diffusely dispersed in the infiltration zone of the tumor and show a strong propensity to invade the surrounding brain along white matter tracts. Although various immune therapies for brain tumors are successful in rodents, there is currently no effective therapy in humans. In the present study, we… Expand
Immunotherapy and checkpoint inhibitors for gliomas
Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model
IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis.
New insights into IL-12-mediated tumor suppression
Transgenic models for cytokine-induced neurological disease.
...
1
2
...

References

SHOWING 1-10 OF 52 REFERENCES
IL-12 Treatment of Endogenously Arising Murine Brain Tumors1
Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.
Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy
Combating immunosuppression in glioma.
Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate‐pulsed dendritic cells in a murine glioma model
  • Oliver M. Grauer, Roger P.M. Sutmuller, +5 authors Gosse J. Adema
  • Medicine
  • International journal of cancer
  • 2008
...
1
2
3
4
5
...